NO20055854L - (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister - Google Patents

(2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister

Info

Publication number
NO20055854L
NO20055854L NO20055854A NO20055854A NO20055854L NO 20055854 L NO20055854 L NO 20055854L NO 20055854 A NO20055854 A NO 20055854A NO 20055854 A NO20055854 A NO 20055854A NO 20055854 L NO20055854 L NO 20055854L
Authority
NO
Norway
Prior art keywords
hydroxy
derivatives
hydroxymethylphenyl
propylphenyl
ethylamino
Prior art date
Application number
NO20055854A
Other languages
English (en)
Inventor
Mark Edward Bunnage
Paul Alan Glossop
Charlotte Alice Louise Lane
Russel Andrew Lewthwaite
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NO20055854L publication Critical patent/NO20055854L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Forehggende oppfinnelse angår forbindelser med formel (1) og fremgangsmåter for fremstilling av intermediater anvendt for fremstilling av sammensetninger som inneholder, og anvendelse av, slike derivater. Forbindelsene ifølge oppfinnelsen er anvendehge overfor et antall sykdommer, forstyrrelser og tilstander, særlig inflammasjons-, allergiske og respirasjonssykdommer, forstyrrelser og tilstander.
NO20055854A 2003-05-15 2005-12-09 (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister NO20055854L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03010944A EP1477167A1 (en) 2003-05-15 2003-05-15 [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
GBGB0329874.2A GB0329874D0 (en) 2003-05-15 2003-12-23 Compounds useful for the treatment of diseases
PCT/IB2004/001519 WO2004100950A1 (en) 2003-05-15 2004-04-29 ‘(2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)-propyl!phenyl derivatives as beta2 agonists

Publications (1)

Publication Number Publication Date
NO20055854L true NO20055854L (no) 2006-02-10

Family

ID=33454327

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055854A NO20055854L (no) 2003-05-15 2005-12-09 (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister

Country Status (29)

Country Link
EP (2) EP1477167A1 (no)
JP (1) JP3966897B2 (no)
KR (1) KR100749990B1 (no)
CN (1) CN1791407A (no)
AP (1) AP2005003443A0 (no)
AR (1) AR044335A1 (no)
AT (1) ATE413879T1 (no)
AU (1) AU2004237952A1 (no)
BR (1) BRPI0410391A (no)
CA (1) CA2525006A1 (no)
CL (1) CL2004000963A1 (no)
CO (1) CO5700776A2 (no)
DE (1) DE602004017710D1 (no)
DK (1) DK1624868T3 (no)
EA (1) EA200501615A1 (no)
EC (1) ECSP056164A (no)
ES (1) ES2314395T3 (no)
GB (1) GB0329874D0 (no)
IS (1) IS8080A (no)
MA (1) MA27840A1 (no)
MX (1) MXPA05012329A (no)
NL (1) NL1026203C2 (no)
NO (1) NO20055854L (no)
OA (1) OA13165A (no)
PA (1) PA8603001A1 (no)
PE (1) PE20060095A1 (no)
TW (1) TW200505865A (no)
UY (1) UY28317A1 (no)
WO (1) WO2004100950A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1708992E (pt) 2004-01-22 2007-11-16 Pfizer Derivados de sulfonamida para o tratamento de doenças
EP1708991B1 (en) 2004-01-22 2007-10-17 Pfizer Limited Sulfonamide derivatives for the treatment of diseases
EA200601510A1 (ru) * 2004-03-17 2007-04-27 Пфайзер Инк. Производные фенилэтаноламина в качестве бета-2-агонистов
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
ATE432278T1 (de) * 2004-03-23 2009-06-15 Pfizer Verbindungen zur behandlung von krankheiten
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
ES2442343T3 (es) 2008-12-30 2014-02-11 Pulmagen Therapeutics (Inflammation) Limited Compuestos de sulfonamida para el tratamiento de trastornos respiratorios
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5629200A (en) * 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
CA2220399A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist

Also Published As

Publication number Publication date
AU2004237952A1 (en) 2004-11-25
EP1477167A1 (en) 2004-11-17
DK1624868T3 (da) 2009-02-23
EP1624868B1 (en) 2008-11-12
WO2004100950A1 (en) 2004-11-25
JP2007503458A (ja) 2007-02-22
DE602004017710D1 (de) 2008-12-24
EP1624868B9 (en) 2009-08-12
KR100749990B1 (ko) 2007-08-16
ECSP056164A (es) 2006-04-19
NL1026203A1 (nl) 2004-11-16
JP3966897B2 (ja) 2007-08-29
IS8080A (is) 2005-10-20
AR044335A1 (es) 2005-09-07
OA13165A (en) 2006-12-13
PE20060095A1 (es) 2006-02-18
CN1791407A (zh) 2006-06-21
CA2525006A1 (en) 2004-11-25
TW200505865A (en) 2005-02-16
ATE413879T1 (de) 2008-11-15
CL2004000963A1 (es) 2005-03-18
AP2005003443A0 (en) 2005-12-31
EA200501615A1 (ru) 2006-06-30
GB0329874D0 (en) 2004-01-28
NL1026203C2 (nl) 2005-07-26
PA8603001A1 (es) 2004-12-16
CO5700776A2 (es) 2006-11-30
BRPI0410391A (pt) 2006-07-18
MXPA05012329A (es) 2006-01-30
EP1624868A1 (en) 2006-02-15
UY28317A1 (es) 2004-12-31
MA27840A1 (fr) 2006-04-03
KR20060017607A (ko) 2006-02-24
ES2314395T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20084005L (no) Aminderivater
NO20051406L (no) Indolderivater som beta-2 agonister
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004080964A8 (en) Indole derivatives useful for the treatment of diseases
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
EA200400892A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
NO20055219L (no) Nye forbindelser
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
EA200601868A1 (ru) 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов
EA200601462A1 (ru) Соединения для лечения заболеваний
EA200601510A1 (ru) Производные фенилэтаноламина в качестве бета-2-агонистов
NO20092413L (no) Pyrazolanaloger
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
NO20064805L (no) Sammensetninger for behandling av sykdommer
ATE317380T1 (de) Bernsteinsäurederivate
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer
UA86615C2 (en) Formamide derivatives useful as adrenoceptor
DOP2004000921A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application